A synthetic peptide for use as a blocking control in assays to test for specificity of DGCR8 antibody, Alternative Names: DGCR8 control peptide, DGCR8 antibody Blocking Peptide, Anti-DGCR8 Blocking Peptide, Digeorge Syndrome Critical Region Gene 8 Blocking Peptide, C22orf12 Blocking Peptide, DGCRK6 Blocking Peptide, Gy1 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
DGCR8
(DiGeorge Syndrome Critical Region Gene 8 (DGCR8))
Hintergrund
DGCR8 contains 2 DRBM (double-stranded RNA-binding) domains and 1 WW domain. It may play a part in the etiology of the velocardiofacial/DiGeorge syndrome (VCFS/DGS), a developmental disorder characterized by structural and functional palate anomalies, conotruncal cardiac malformations, immunodeficiency, hypocalcemia, and typical facial anomalies.